FPRX Five Prime Therapeutics, Inc.

34.89
-1  -3%
Previous Close 36.05
Open 36.04
Price To book 2.53
Market Cap 959.79M
Shares 27,509,000
Volume 511,603
Short Ratio 9.22
Av. Daily Volume 404,840

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dose expansion phase initiated May 2016. Enrollment to be completed 2H 2017. Data due 2017.
FPA008
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
FP-1039
Mesothelioma cancer

Latest News

  1. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  2. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Five Prime Therapeutics Announces Executive Changes
  4. Coverage initiated on Five Prime Therapeutics by Instinet
  5. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017
  6. FIVE PRIME THERAPEUTICS INC Financials
  7. FIVE PRIME THERAPEUTICS INC Files SEC form 10-K, Annual Report
  8. Edited Transcript of FPRX earnings conference call or presentation 23-Feb-17 9:30pm GMT
  9. Five Prime Therapeutics posts 4Q loss
  10. Five Prime Therapeutics posts 4Q loss
  11. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  12. Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results
  13. Q4 2016 Five Prime Therapeutics Inc Earnings Release - After Market Close
  14. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
  15. Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on February 23
  16. Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
  17. Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting
  18. Cabiralizumab From Five Prime Therapeutics Inc (FPRX) Obtains Orphan Designation
  19. European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis (PVNS)
  20. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu